reSET for the Treatment of Stimulant Use in HIV Clinics: Care Optimization Supporting Treatment Adherence (COSTA)
Recruiting now · Not applicable
Conditions studied: Stimulant Use Disorder, People Living With HIV
In brief
The purpose of this study is to find out if reSET, an FDA authorized mobile therapeutic, is effective in treating stimulant use disorder and helping keep HIV viral load suppression stable among men who have sex with men who are living with HIV and have a stimulant use disorder.
Key facts
- Study ID
- NCT05958017
- Run by
- University of Miami
- People needed
- 260
- Starts
- 2025-03-04
- Expected to finish
- 2028-01-31
- Last updated by the study team
- 2026-06-17
Who can join
Age: 18 and older, up to 90. Sex: male. Healthy volunteers: not accepted.
You may qualify if…
- Assigned male sex at birth and has not undergone any transgender hormonal treatment
- Reports having had sex with a male in the past 12 months
- Age 18 or older
- Is affiliated with a study referral source (e.g., AHF clinic, registry, other healthcare program or clinic) or resides in a city or county where a participating healthcare center or health program is located
- Screens positive for mild, moderate or severe stimulant use disorder in the last 12 months using the MINI
- Reports that he is not currently in drug treatment
- Is living with HIV
- Reports having an active antiretroviral prescription
- Have access to a smartphone or tablet with stable internet at least twice a week and can download applications to the smartphone or tablet
- Able to understand English
- Consents to participation in the study
- Provides sufficient locator information
- Identifies as non-Hispanic White, non-Hispanic Black/African American or Latinx/Hispanic
- Has been in stable housing for the past 3 months and intends to remain housed for the next 15 months
You may not qualify if…
- Patient appears to have diminished capacity to consent either because of cognitive impairment or severe psychiatric symptoms (e.g., mania, psychosis).
- Persons that meet criteria for prisoner status will be excluded at baseline.
- Patients who screen positive for moderate to severe opioid use disorder will be excluded from the study because effective pharmacological agents exist for the treatment of this disorder. These patients will be referred to community-based programs that provide specialized treatment for this disorder.
- Participants will be excluded prior to randomization, if they do not complete at baseline the Time-Line Follow-Back or the laboratory visit.
Where it is running
- University of Miami — Miami, Florida, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.